We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test Preferable to Skin Test for TB Diagnosis

By LabMedica International staff writers
Posted on 06 Jul 2010
A highly accurate blood test for the diagnosis of tuberculosis (TB) is preferable to the Mantoux or tuberculin skin test (TST).

New guidelines published by the [U.S.] Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) indicate that a one-step blood test is far superior to the archaic TST. More...
Results of the blood test are ready within 24 hours and do not require a return visit from the patient.

Interferon Gamma Release Assays (IGRAs) are simple blood tests that accurately identify people infected with Mycobacterium tuberculosis, the causative agent of TB. Unlike the TST, where the results are open to interpretation, IGRAs are accurate, sensitive, and specific for the disease. The guidelines recommend the assay over the TST for testing persons who have received Bacille Calmette-Guerin (BCG) injections, as a vaccine or for cancer therapy. Another reason for the preference is for diagnosing TB infection for persons from groups that historically have low rates of returning to have TSTs read. IGRAs may be used in place of TST (without preference) to test recent contacts of persons with infectious TB or for periodic screening to address occupational exposure to TB.

The QuantiFERON-TB Gold Test (QFT) is an IGRA manufactured by Cellestis International Pty Ltd. (Chadstone, Australia). QFT is available for use in all clinical settings in which TST is commonly used. Examples include contact tracing, regular employee testing, for example for health care workers, as well as screening programs for prisoners and immigrants. QFT's application in the screening of immunosuppressed patients prior to antitumor necrosis factor-alpha therapy initiation and in patients with human immunodeficiency virus (HIV), cancer, or organ transplants offers distinct advantages over the TST.

Antonino Catanzaro, M.D., professor of medicine, University of California (UCSD; San Diego, USA), said, "These guidelines encapsulate the enormous body of clinical evidence on the performance of the QFT test and reflect the significant benefits this test is bringing to TB control worldwide." It is estimated that one person dies of TB every 17 seconds, causing nearly two million deaths annually. Multi-drug resistant TB is becoming an increasing problem worldwide.

Related Links:
[U.S.] Centers for Disease Control and Prevention
Cellestis International Pty Ltd.
University of California San Diego




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.